How Much Does Rapamycin (Sirolimus) Cost in North Dakota in 2026?

Retail Cash Price for Sirolimus in North Dakota

The average cash price for generic sirolimus across North Dakota retail pharmacies sits at approximately $80 per month in 2026. That figure reflects a 30-day supply at standard transplant dosing (2 mg daily). Off-label longevity protocols typically call for once-weekly dosing of 3 to 6 mg, which means a single month's supply may stretch to several months of use.

Pricing varies by pharmacy. Bismarck and Fargo chain pharmacies tend to cluster near the $80 average, while independent pharmacies in smaller communities like Williston or Dickinson may charge $90 to $110 depending on their wholesaler agreements. The branded product, Pfizer's Rapamune, lists at roughly $600 per month, but generic competition has driven actual out-of-pocket costs well below that figure since sirolimus first went generic in 2014 1.

A key cost variable is whether you fill for a transplant indication or an off-label longevity protocol. Transplant patients on daily dosing pay more per month than longevity users taking a single weekly dose. A patient filling twelve 6 mg tablets for twelve weeks of once-weekly dosing may pay as little as $25 to $35 per month when the math is spread across the actual supply duration.

GoodRx and RxSaver coupons can reduce the retail cash price by 10 to 30 percent at participating North Dakota pharmacies, bringing the effective cost for a 30-day transplant supply below $60 in some cases. These coupons are free to use and do not require insurance.

Compounded Sirolimus Pricing and Legality in North Dakota

Compounded sirolimus is legal in North Dakota when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. North Dakota follows federal guidelines under the Drug Quality and Security Act (DQSA), which permits 503A pharmacies to compound medications that are not commercially available in the prescribed form, strength, or combination.

Compounded sirolimus in North Dakota averages about $120 per month. This is higher than generic retail pricing because compounding pharmacies produce custom formulations (topical creams, low-dose capsules, flavored suspensions) that require specialized preparation. Some longevity clinics prefer compounded formulations because they can specify exact weekly doses in a single capsule, simplifying the patient experience.

Not every pharmacy in North Dakota compounds sirolimus. The state has a limited number of 503A-licensed compounding pharmacies. Many patients order from out-of-state 503A pharmacies that ship directly to North Dakota addresses. This is legal under federal law as long as the pharmacy holds the appropriate state and federal licenses, the prescription originates from a valid prescriber-patient relationship, and the compound is for an individual patient 2.

When deciding between generic tablets and compounded capsules, consider three factors: your prescribed dose (if it matches a commercially available tablet strength, generic is cheaper), your preferred dosing schedule (compounding can create exact weekly-dose capsules), and whether you need a non-standard form like a topical preparation.

North Dakota Medicaid and Sirolimus Coverage

North Dakota Medicaid does not cover sirolimus for off-label longevity indications. This is consistent with nearly every state Medicaid program in the country, none of which list geroprotective or anti-aging applications as covered uses for mTOR inhibitors.

For FDA-approved transplant indications, sirolimus may be covered under North Dakota Medicaid's pharmacy benefit with prior authorization. The state uses a preferred drug list (PDL) managed by the North Dakota Department of Health and Human Services. Transplant immunosuppressants generally receive coverage when prescribed within labeling, but the specific tier placement and prior authorization requirements change with each PDL update cycle.

Patients on Medicaid who receive a kidney transplant and require sirolimus as part of their immunosuppressive regimen should work with their transplant center's financial coordinator to obtain prior authorization. Denial rates for transplant-indication sirolimus are low when documentation includes the transplant date, current regimen, and rationale for sirolimus over alternative agents like tacrolimus or mycophenolate 3.

For off-label longevity use, Medicaid beneficiaries in North Dakota will need to pay out of pocket. The $80 generic cash price or the $120 compounded price applies. No state-funded discount program specifically targets sirolimus for non-transplant use.

Private Insurance Coverage in North Dakota

Commercial insurance coverage for sirolimus in North Dakota depends on the indication, the insurer, and the specific plan formulary. The major carriers operating in the state (Blue Cross Blue Shield of North Dakota, Sanford Health Plan, Medica, and UnitedHealthcare) all include generic sirolimus on their formularies for transplant indications. Copays typically range from $15 to $50 for a 30-day supply under most commercial plans.

Off-label prescriptions face a different reality. Insurers are not required to cover medications prescribed for non-FDA-approved uses unless the off-label indication is supported by a recognized compendium (such as the AHFS Drug Information compendium or Micromedex DrugDex). Longevity and geroprotection are not currently listed in any major compendium as supported indications for sirolimus, so most commercial plans will deny coverage.

Some patients have reported success obtaining coverage by framing the prescription around a secondary indication that the insurer recognizes. For example, sirolimus has documented immunomodulatory effects that may be relevant to certain autoimmune conditions 4. This is a conversation to have with your prescribing physician, not a billing strategy to attempt independently.

Self-funded employer plans (ERISA plans) have more flexibility than fully insured plans because the employer, not the insurance carrier, makes coverage decisions. Employees at large North Dakota employers (Bobcat, Basin Electric, Microsoft's Fargo campus) may find that their self-funded plan will cover sirolimus with appropriate clinical documentation, even for off-label uses. Appeals that include peer-reviewed literature supporting the clinical rationale have a higher success rate than bare prior authorization requests.

Telehealth Access to Sirolimus in North Dakota

Telehealth prescribing of sirolimus is permitted in North Dakota. The state's telehealth parity law (NDCC 26.1-36-09.15) requires insurers to cover telehealth services on the same terms as in-person visits, and the North Dakota Board of Medicine permits physicians licensed in the state to prescribe controlled and non-controlled substances via telehealth when a valid prescriber-patient relationship exists.

Sirolimus is not a controlled substance. It is classified as a prescription-only immunosuppressant, which means any physician with an active North Dakota medical license (or a license in a compact state with appropriate telehealth registration) can prescribe it after an appropriate clinical evaluation conducted via video or audio visit.

Several national longevity-focused telehealth platforms now serve North Dakota patients. These platforms typically charge a consultation fee ($99 to $250 for an initial visit) and then write the prescription to a pharmacy of the patient's choice. Some partner directly with compounding pharmacies and bundle the medication cost into a monthly membership fee ranging from $150 to $250 per month, which includes the compounded sirolimus, periodic lab monitoring orders, and follow-up consultations.

For patients who prefer to separate the clinical relationship from the pharmacy transaction, a telehealth consultation followed by a prescription sent to a local Fargo or Bismarck retail pharmacy for generic sirolimus fill is the most cost-effective approach. The consultation fee plus the $80 generic price yields a total monthly cost well below the bundled membership model.

Lab monitoring is an important consideration regardless of access route. Sirolimus requires periodic assessment of lipid panels, complete blood counts, and renal function. The PEARL trial, which evaluated rapamycin in healthy older adults, confirmed that low-dose weekly sirolimus was generally well tolerated but did produce mild increases in LDL cholesterol and triglycerides in some participants 4. Standard monitoring intervals are every 3 to 6 months for longevity-dose patients and monthly for transplant patients during the first year.

Discount Programs and Savings Strategies

No manufacturer copay card from Pfizer currently applies to generic sirolimus. Pfizer's savings programs for Rapamune (the branded product) are limited to commercially insured patients and typically reduce the branded copay to $0 to $25 per month. These cards do not work with Medicaid, Medicare, or other government-funded insurance.

For uninsured or underinsured North Dakota patients paying cash, the most effective savings strategies are:

GoodRx or RxSaver coupons. These free discount tools aggregate negotiated rates from pharmacy benefit managers. Generic sirolimus 1 mg tablets (quantity 60, for a 2 mg daily transplant dose) can be found for $55 to $75 at North Dakota Walgreens, CVS inside Target, and Thrifty White locations using these coupons. Prices fluctuate, so checking both platforms before filling is worthwhile.

90-day fills. Many North Dakota pharmacies offer a lower per-unit price on 90-day supplies compared to three separate 30-day fills. The savings typically amount to 10 to 15 percent. Mail-order pharmacies like Cost Plus Drugs (Mark Cuban's company) and Amazon Pharmacy also ship to North Dakota and may undercut local retail pricing on generic sirolimus.

Patient assistance programs. Pfizer's Pfizer Oncology Together program and the HealthWell Foundation both offer copay assistance for sirolimus, but eligibility is generally restricted to patients with FDA-approved indications (transplant, lymphangioleiomyomatosis) and documented financial need. Off-label longevity users typically do not qualify.

503B outsourcing facilities. Unlike 503A pharmacies that compound per individual prescription, 503B facilities produce larger batches under current good manufacturing practice (cGMP) conditions. Some longevity clinics source sirolimus from 503B facilities and pass volume pricing to patients. This model is less common in North Dakota but available through telehealth platforms that partner with national 503B pharmacies 5.

Clinical Context: Why Rapamycin Costs What It Does

Sirolimus was first approved by the FDA in 1999 for prevention of organ rejection in renal transplant recipients 1. Pfizer (which acquired the product through its Wyeth acquisition) held patent exclusivity until generic entry began in 2014. The arrival of generic manufacturers (Greenstone, Zydus, Biocon) collapsed the price from over $1,000 per month to the current $80 average for cash-pay patients.

The recent surge in demand for sirolimus as a geroprotective agent has not significantly affected pricing because the drug remains off-patent and multiple generic manufacturers compete for market share. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, was the first placebo-controlled randomized trial of rapamycin in healthy older adults (N=150). The trial found that 5 mg weekly sirolimus for 12 months was generally well tolerated, with a side effect profile comparable to placebo for most endpoints, though participants showed a statistically significant increase in LDL cholesterol (mean +12 mg/dL, P=0.003) 4.

The Targeting Aging with Metformin (TAME) trial and the Dog Aging Project's rapamycin arm continue to generate public interest in mTOR inhibition as a longevity intervention 6. As Dr. Matt Kaeberlein, former director of the University of Washington Healthy Aging and Longevity Research Institute, has noted: "Rapamycin is the most reproducible pharmacological intervention to extend lifespan across species, from yeast to mammals." This preclinical track record, combined with emerging human data, drives the growing off-label demand.

A second perspective from the clinical side: Dr. Andrea Maier, co-director of the Centre for Healthy Longevity at the National University of Singapore, has stated that "the safety profile of low-dose intermittent rapamycin in healthy adults appears favorable based on early trial data, but we need larger and longer studies before recommending it broadly." The distinction between weekly low-dose protocols (3 to 6 mg once per week) and daily transplant-dose regimens (2 mg or more per day) is clinically significant. Side effects like mouth ulcers, hyperlipidemia, and immunosuppression are dose-dependent and occur far less frequently at longevity doses than at transplant doses 7.

What North Dakota Patients Should Know Before Starting

Sirolimus requires a prescription in all 50 states. No pharmacy in North Dakota can legally dispense it without one. Patients interested in rapamycin for longevity should establish a relationship with a prescriber (either a local physician or a licensed telehealth provider) who is familiar with mTOR inhibitor pharmacology and willing to monitor labs at appropriate intervals.

Baseline labs before starting sirolimus should include a comprehensive metabolic panel, fasting lipid panel, complete blood count with differential, and hemoglobin A1c. Fasting glucose monitoring is relevant because mTOR inhibition can impair glucose tolerance at higher doses, though this effect is less pronounced with weekly dosing 8. Patients with pre-existing hyperlipidemia or diabetes should discuss risk-benefit tradeoffs with their prescriber before initiating therapy.

For transplant patients in North Dakota, sirolimus is typically managed by the transplant center (most commonly Sanford Health in Fargo or referral centers in Minneapolis). These patients should not adjust doses, switch pharmacies, or transition to compounded formulations without explicit guidance from their transplant team. Trough level monitoring (target 4 to 12 ng/mL for most protocols) is mandatory for transplant-dose sirolimus and requires periodic blood draws timed 24 hours after the last dose 1.

Generic sirolimus tablets should be stored at controlled room temperature (20 to 25°C) and protected from light. Compounded liquid formulations may require refrigeration depending on the compounding pharmacy's beyond-use dating. Always verify storage instructions with your dispensing pharmacy.